Intercept’s US president Vivek Devaraj said the pharma company still believes in the evidence supporting the liver disease ...

This article explores how eating junk food raises the risk of fatty liver diseases, examines symptoms, and highlights ...

In the US, viral HCC has decreased while HCC incidence due to chronic alcohol-associated liver disease and metabolic ...

Nonalcoholic fatty liver disease is the most common liver disease in America. If you have any of these fatty liver symptoms ...

New insights and emerging scientific trends incorporated into our ACLF development plan, with data readout from 4 clinical trials anticipated by the end of 2025, including data from 3 new clinical ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

Pharma Two B Ltd. (“Pharma Two B”), a late-clinical stage company that is developing P2B001, an innovative combination product candidate for the treatment of Parkinson’s Disease (“PD”) and Hepion ...

Research Progress on Multidisciplinary Intervention for Metabolic Dysfunction-Associated Steatotic Liver Disease and Related Liver Cancer ...

A new study highlights how signals from the liver to the brain influence eating patterns tied to our circadian rhythms.

Learn about HMGB1's crucial role in liver diseases, its pathways and therapeutic potential that can treat liver diseases.

CONSHOHOCKEN, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences: UBS Global Healthcare ...